|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Abbott Labs has granted Ikonisys, Inc. license and supply rights to certain DNA probe technology for use with the proprietary Celloptics technology platform developed by Ikonisys. Ikonisys acquired a worldwide license under Abbott patents for the manufacture and sale of DNA probes in conjunction with Chromotest, a test for the prenatal diagnosis of chromosomal abnormalities using fetal cells from the maternal circulation. The companies also signed a probe supply agreement granting Ikonisys rights to purchase from Abbott chromosome fluorescence in situ hybridization (FISH) probes in the fields of pre-implantation genetic diagnosis and automated detection in amniocytes of FISH signals of the most common chromosomal abnormalities. AcroMetrix Corporation signed an agreement with Ambion Diagnostics, a division of Ambion, Inc. to manufacture Armored RNA-based products and distribute them to in vitro diagnostic laboratories and manufacturers. Ambion Diagnostics will supply AcroMetrix with custom products based upon Armored RNA technology for further development and incorporation into calibrators, validation panels, proficiency panels and single point controls or standards. Ambion Diagnostics, a division of Ambion, Inc. introduced its first molecular genetic test, Signature CF 2.0 ASR, for the detection of mutations in the gene associated with cystic fibrosis. The test is adapted for a bead array platform and can identify 25 mutations and 6 variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene as recommended by the American College of Medical Genetics (ACMG). Bayer HealthCare Diagnostics Division is collaborating with Oxford Genome Sciences (OGeS) to develop OGeS' proteomics platform and Oxford Genome Anatomy Project (OGAP) proteomics database, to evaluate biomarkers for breast cancer management. The biomarkers for breast cancer were identified by Bayer HealthCare. GenoMed, Inc. has introduced its HealthChip made up of thousands of cancer-associated genotypes that have the potential to serve as an early warning system for the top six common cancers: breast, colon, lung, ovarian, pancreatic, and prostate. IntegraGen opened its first genetic testing facility in Bonn, Germany. The Expert Center will provide comprehensive laboratory testing combined with supporting genetic counseling. The first test to be offered will be for the diagnosis of Maturity Onset Diabetes of the Young (MODY), a form of type 2 diabetes that is often mistaken for type 1 diabetes. Nanogen, Inc. and Pathway Diagnostics entered into a nonexclusive, worldwide license agreement under which Nanogen will develop diagnostic products that detect genetic variations associated with responses to antidepressant and antipsychotic therapeutics. The companies have begun work on developing a molecular diagnostic product that could be used to select the most appropriate drug and dosage for patients treated for psychiatric diseases. Tessera, Inc. released its first product, ProstaMark EPCA (Early Prostate Cancer Antigen), as an tissue biopsy Analyte Specific Reagent (ASR). The EPCA test is now available at Unipath, LLC and will soon be offered by pathology laboratories throughout the U.S. Xenomics, Inc. has developed a technology to detect tuberculosis Transrenal-DNA (Tr-DNA) in the urine of infected patients. Xenomics' technology also has the ability to use a single urine specimen to simultaneously detect both HIV and the common tuberculosis infections that occur opportunistically in immune-compromised AIDS patients.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: April 4, 2005 |
![[Page Banner Image]](images/hmole.gif){kind=small}
